This briefing paper gives an overview of the development of drug policies within the European Union, and the institutions and structures that exist to implement and evaluate these policies. Taking the EMCDDA Report 2006, and the European Commission 2006 Progress Review as their starting point, the IDPC analyses the strengths and weaknesses of current arrangements, and makes some recommendations for future action.